SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Amgen Sjogren's Drug Cuts Disease Activity in Trial

Amgen's Sjogren's drug reduced disease activity in a clinical trial.

AMGN
SquawkNews Desk 1 updates Updated Nov 11, 2026, 01:59 PM UTC

Story updates

01:59:01 PM UTC
SquawkNews
Amgen NASDAQ:AMGN said on Wednesday a detailed late-stage trial data showed its experimental drug for the Sjogren's disease significantly reduced disease activity in patients.

Related stories

MSC Nears Deal to Acquire 80% Stake in Meyer Werft, Spiegel Reports The German government and Lower Saxony are nearing a deal giving Geneva-based shipping group MSC the right to acquire about 80% of the German shipbuilder's shares, Spiegel reported M impact | EQUITY | Nov 14, 2026, 12:11 PM UTC Advanta Agrees to Acquire Hytech Egypt Holding Company Advanta entered into an agreement on Aug. 15, 2026, to acquire Hytech Egypt USA LLC, the holding company of Misr Hytech Seed International, from Helios Investment Partners and The M impact | EQUITY | Nov 14, 2026, 11:51 AM UTC Microsoft Restores Microsoft 365 After Global Outage Microsoft said it restored Microsoft 365 services after a global outage disrupted Outlook, Teams and other applications for more than 24 hours. The company said the disruption was M impact | EQUITY | Nov 14, 2026, 10:41 AM UTC Microsoft Restores Service After Widespread Outage Microsoft said full service to its products was restored as of early Saturday, including processing undelivered emails. M impact | EQUITY | Nov 14, 2026, 09:57 AM UTC Microsoft Restores Services After Hourslong Global Outage Microsoft said services were fully restored after an hourslong global outage. M impact | EQUITY | Nov 14, 2026, 09:12 AM UTC Rs.4K cr Ramayana movie VFX maker parent Prime Focus shares in focus after 14x profit jump in Q2; stock up 61% in a year New Delhi, Nov. 14 -- Prime Focus Ltd, the parent company of visual effects and animation studio DNEG, is likely to remain in focus on Monday after announcing its September-quarter L impact | EQUITY | Nov 14, 2026, 09:04 AM UTC